Literature DB >> 3543365

Structure-activity relationships of sparsomycin and its analogues. Inhibition of peptide bond formation in cell-free systems and of L1210 and bacterial cell growth.

L A van den Broek, R M Liskamp, J H Colstee, P Lelieveld, M Remacha, D Vázquez, J P Ballesta, H C Ottenheijm.   

Abstract

The biological activity of 14 analogues of sparsomycin (1) was studied in cell-free systems of Escherichia coli, Saccharomyces cerevisiae, and Sulfolobus solfataricus by measuring the inhibition of protein synthesis. The inhibition of L1210 colony formation in soft agar and bacterial cell growth in solid as well as in liquid medium was also examined. Each analogue possesses not more than two structural modifications of the sparsomycin molecule. This enabled us to determine unambiguously several structural and stereochemical features that are required for an optimal biological activity in these assays. Sparsomycin, having the SCRS chirality, is the most potent of the four possible stereoisomers. The results obtained with compounds 5-7 indicate that the presence of an oxygen atom on the S (alpha) atom is essential. Substitution of the bivalent sulfur atom by a CH2 group (10) or of the SCH3 moiety by a Cl atom (12) affects the activity of the molecule partially. Compound 12 is surprisingly active against intact cells. Substitution of the C(6)-CH3 group by a H(14) reduces the activity of the molecule. Isomerization of the trans double bond into the cis double bond yields cis-sparsomycin (15), which is inactive. The hydrophobic derivatives 8, 9, and 11 are considerably more active than sparsomycin; thus the ribosomal binding site for sparsomycin may have a hydrophobic character.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3543365     DOI: 10.1021/jm00385a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Interaction of the antibiotic sparsomycin with the ribosome.

Authors:  E Lazaro; A San Felix; L A van den Broek; H C Ottenheijm; J P Ballesta
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; M Garzotto; T B Vree; E van der Kleijn; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

3.  Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; P Fernandez del Moral; H van Rennes; J M Wessels; B Winograd; E van der Kleijn; T B Vree; U van Haelst; L A van den Broek
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.

Authors:  Z Zylicz; D J Wagener; H van Rennes; E van der Kleijn; P Lelieveld; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

5.  Characterization of sparsomycin resistance in Streptomyces sparsogenes.

Authors:  E Lázaro; E Sanz; M Remacha; J P G Ballesta
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

6.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

7.  A spontaneous point mutation in the single 23S rRNA gene of the thermophilic arachaeon Sulfolobus acidocaldarius confers multiple drug resistance.

Authors:  C Aagaard; H Phan; S Trevisanato; R A Garrett
Journal:  J Bacteriol       Date:  1994-12       Impact factor: 3.490

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.